Exelan Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exelan Pharmaceuticals Inc.
How Cipla Is Aligning Manufacturing Amid The Pandemic
Cipla senior management executive tells Scrip how the company is calibrating manufacturing as part of a wider business “reimagination” and accelerated digital adoption across its operations.
Decade In Review: C-Suite Shifts At Family-Owned Indian Firms
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Cipla Acquires Avenue, Primes Play In Pain Amid US Opioid Crisis
Cipla has struck a 'de-risked' deal to acquire the specialty firm Avenue Therapeutics, Inc, for up to $215m as it readies a niche play in the US pain management segment amid the opioid crisis.
Cipla 2.0: ‘Disproportionate’ US Growth, Getting The Profit Curve Right
Cipla is planning an ambitious growth trajectory, aiming to propel its US business “towards a $1bn generic enterprise” and develop a strong specialty franchise focused on its traditional stronghold, the respiratory segment, and the CNS space.
- Generic Drugs
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.